It goes without saying that the US cannabis market has grown significantly in the last few years. And slowly but surely, American cannabis stocks are starting to reap the benefits.
Milestones in the US cannabis space have been coming quickly, with recent developments including the news that four US states voted in favor of recreational marijuana use on election day: California, Florida, Nevada and Massachusetts. Florida also voted to increase the number of conditions that can be treated with medical marijuana.
Other key developments include Colorado crossing the $1-billion mark for annual marijuana sales and the New York Stock Exchange listing a cannabis company for the first time.
And that’s only the beginning — by 2020, the US cannabis market is expected to generate $2.3 billion in tax revenue. What’s more, in 2017 alone, US states where cannabis is legal are expected to earn roughly $655 million in sales taxes. Of that amount, $559 million will be from cannabis-specific taxes.
Of course, there is certainly still work to be done to legalize cannabis on a federal level in the US. Even so, it has never been a more exciting time for American cannabis stocks. With that in mind, here’s a look at a 10 publicly traded American marijuana stocks.
American Cannabis Company (OTCMKTS:AMMJ)
American Cannabis Company was founded in 2013 and provides consulting and product solutions for the medical, adult-use and low-THC regulated cannabis markets. The company’s portfolio of products includes The Satchel, SoHum Living Soils, Cultivation Cube and the High Density Cultivation System. It is also responsible for establishing the Geoponics Methodology of cultivation.
In addition to the products and cultivation methods it has created, American Cannabis Company has helped its clients win over 13 cannabis licenses in eight US states. It has also helped two companies secure operational approvals from Health Canada.
On March 22, the company announced the approval of state application materials for its Pennsylvania clients. Prior to that, American Cannabis secured a contract and equity stake with a client in Florida.
Terra Tech (OTCMKTS:TRTC)
Terra Tech is focused on integrating natural resources with technology to create solutions for medical cannabis production, extraction and distribution. The company is also focused on plant science research and development, food production and closed-environment agriculture.
Through its subsidiaries, Terra Tech is committed to advancing research in the medical cannabis industry. Its subsidiaries include: Blum, which operates in the medical cannabis space; MediFarm, a medical cannabis company that manages RFP processes and obtains permits for marijuana cultivation, production and dispensaries; and GrowOp Technology, which specializes in the design and manufacturing of horticulture equipment for cultivation systems.
On March 10, Terra Tech signed a lease for a 13,000-square-foot cannabis cultivation complex in Oakland.
GW Pharmaceuticals (OTCMKTS:GWPRF)
GW Pharmaceuticals is headquartered in the UK, and has operations both there and in the US. The company developed Sativex, the world’s first prescription medicine from the cannabis plant, and it has been approved in roughly 29 countries outside of the US for treatments related to multiple sclerosis.
The company has been researching cannabinoids since 1998. Now its primary focus is on disorders affecting the central nervous system, including epilepsy.
Insys Therapeutics (NASDAQ:INSY)
Insys Therapeutics is a pharmaceutical company that uses proprietary sublingual spray technology to develop pharmaceutical cannabinoids. It is focused on developing products to address unmet medical needs in existing commercial products.
In February, the company announced that it is providing for the use of cannabidiol oral solution in compassionate-use studies in subjects with refractory pediatric epilepsy.
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Zynerba Pharmaceuticals is focused on assisting patients with severe health conditions through synthetic cannabinoid therapeutics. The health conditions it is attempting to treat include refractory epilepsy, osteoarthritis, Fragile X syndrome, fibromyalgia and peripheral neuropathic pain.
Currently the company has two treatment products. One is ZYN002, a CBD gel that is a non-psychoactive cannabinoid. Currently ZYN002 is in Phase 2 clinical development for patients with epilepsy, osteoarthritis in the knee and Fragile X syndrome.
The second product is ZYN001, a THC pro-drug patch. It’s a treatment that enables delivery through the skin and into the circulatory system through a patch. A Phase 1 clinical trial for ZYN001 is expected to begin in the first half of 2017.
Cannabics Pharmaceuticals (OTCMKTS:CNBX)
Cannabics Pharmaceuticals is focused on personalized anti-cancer and palliative treatments. Right now the company is developing natural cannabinoid products based on diagnostic procedures for cancer treatment and its side effects. The company’s capsules are used for patients who have advanced stages of cancer and are aimed atprolonging and improving quality of life.
In February, Cannabics announced the initial commercialization of cannabinoid-based personalized diagnostics for cancer patients. As per a press release, a test using CTGC technology can obtain cancer cells from a patient’s blood samples and then test their sensitivity to cannabinoid compounds.
United Cannabis (OTCMKTS:CNAB)
Since 2009, United Cannabis has been focused on the cannabis sector in Colorado. Once marijuana was legalized in the state, the company began working closely with patients suffering from chronic conditions and other diseases.
United Cannabis now has over 15,000 patients, and continues to look at advancing cannabinoids in medicine. In particular it is focused on refining genetics for medical-grade strains of plants containing high amounts of CBD. Most recently, United Cannabis entered into a licensing agreement with Vessel Life Science to produce and distribute products in Pennsylvania.
General Cannabis (OTCMKTS:CANN)
General Cannabis labels itself as a “trusted partner” to the cultivation, production and retail sectors of the cannabis industry. The company has a real estate operating division, and it also does consulting and financing. In addition, it aids in the distribution of infrastructure products designed to help facilities and dispensaries succeed.
The company has a number of subsidiaries, including: Next Big Crop, Chiefton Supply, Iron Protection Group and Chiefton Design.
Cannabis Sativa (OTCMKTS:CBDS)
Located in Nevada, Cannabis Sativa is largely focused on branding legal cannabis and hemp products. It also has a number of subsidiaries, including: Wild Earth Naturals, CBDS, hi Brand International, hi Benefits Card, Cannbidoil Infused Bottled Water and CBD Capsules.
Cannabis Science (OTCMKTS:CBIS)
Much like many of the other companies on this list, Cannabis Science is focused on providing treatment options for unmet medical needs. In particular, the company is focused on treating patients with life-threatening and debilitating conditions. Most recently, Cannabis Science received notice for its first greenhouse orders.
Is there an American cannabis stock you think should be on this list? Let us know in the comments — we’ll be updating it in the future.
Don’t forget to follow us @INN_Resource for real-time news updates!
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.